Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 12:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Hepatic Impairment
Interventions
sitravatinib
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
5
States / cities
Tustin, California • Miami, Florida • Orlando, Florida + 2 more
Conditions
Healthy Adults
Interventions
Sitravatinib 50 mg, Sitravatinib 100 mg, Itraconazole, Rifampin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Terminated Phase 2 Interventional Results available

Sitravatinib in Metastatic Breast Cancer

NCT04123704
Conditions
Breast Cancer Stage IV, Triple Negative Breast Cancer, Breast Neoplasms, Breast Cancer Metastatic
Interventions
Sitravatinib
Drug
Lead sponsor
Xiang Zhang
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
Interventions
Sitravatinib, Nivolumab, Pembrolizumab, Enfortumab vedotin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
36
States / cities
Tucson, Arizona • Irvine, California • Aurora, Colorado + 30 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Explore the Effect of Acid-reducing Agents

NCT04935112
Conditions
Healthy Adults
Interventions
Sitravatinib, Pantoprazole, Famotidine
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Healthy Adults
Interventions
sitravatinib
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas